The estimated Net Worth of Steven Sobieski is at least $3.43 Million dollars as of 30 June 2014. Steven Sobieski owns over 8,000 units of Insulet stock worth over $2,732,760 and over the last 17 years Steven sold PODD stock worth over $700,000.
Steven has made over 2 trades of the Insulet stock since 2012, according to the Form 4 filled with the SEC. Most recently Steven sold 8,000 units of PODD stock worth $320,000 on 30 June 2014.
The largest trade Steven's ever made was selling 20,000 units of Insulet stock on 8 June 2012 worth over $380,000. On average, Steven trades about 2,333 units every 63 days since 2008. As of 30 June 2014 Steven still owns at least 12,000 units of Insulet stock.
You can see the complete history of Steven Sobieski stock trades at the bottom of the page.
Steven's mailing address filed with the SEC is C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD, MA, 01730.
Over the last 18 years, insiders at Insulet have traded over $64,849,299 worth of Insulet stock and bought 175,262 units worth $7,280,516 . The most active insiders traders include Jonathan Silverstein, Elizabeth H Weatherman, and Samuel D Colella. On average, Insulet executives and independent directors trade stock every 19 days with the average trade being worth of $2,473,148. The most recent stock trade was executed by Timothy J Scannell on 10 September 2024, trading 5,000 units of PODD stock currently worth $1,129,200.
insulet corporation is an innovative medical device company based in billerica, massachusetts. it was founded in 2000 with the mission of improving the lives of people with diabetes. specifically, through its revolutionary omnipod insulin management system, insulet seeks to expand the use of insulin pump therapy. studies have demonstrated the advantages of insulin pump therapy over multiple daily insulin injections (mdi); these advantages include better glycemic control, fewer hypoglycemic events, reduced glycemic variability1 and improved quality of life2. despite these benefits, most people still choose mdi therapy largely due to the complexity, cost and inconvenience of conventional pump technology. the omnipod is a discreet and easy-to-use system that eliminates many of the issues associated with conventional pumps. improvements include omnipod's lack of tubing; automated, virtually pain-free insertion; and two straightforward parts that communicate wirelessly. by breaking down
Insulet executives and other stock owners filed with the SEC include: